

Serial No. 09/096,247

~~Office Action mailed on April 6, 1999. Please cancel all claims and enter the following new claims.~~

1. A solution formulation comprising: a physiologically tolerated buffer selected from the group consisting of TRIS and arginine; a monomeric insulin analog wherein the insulin analog is Lys^{B28}Pro^{B29}-human insulin; zinc; and a phenolic preservative.
2. The formulation of Claim 1, wherein the buffer is TRIS.
3. The formulation of Claim 2 further comprising an isotonicity agent and wherein the pH of the formulation is between pH 7.0 and pH 8.0 when measured at a temperature of 22°C.
4. The formulation of Claim 3, wherein the concentration of Lys^{B28}Pro^{B29}-human insulin is between about 1.2 mg/mL and about 50 mg/mL.
5. The formulation of Claim 4, wherein the concentration of Lys^{B28}Pro^{B29}-human insulin is between about 3.0 mg/mL and about 35 mg/mL.
6. The formulation of Claim 5, wherein the concentration of Lys^{B28}Pro^{B29}-human insulin is between about 3.5 mg/mL and about 35 mg/mL.
7. The formulation of Claim 6, wherein the concentration of Lys^{B28}Pro^{B29}-human insulin is between about 7 mg/mL and about 35 mg/mL.
8. The formulation of Claim 7, wherein the concentration of Lys^{B28}Pro^{B29}-human insulin is between about 14 mg/mL and about 35 mg/mL.

J. S. -2-

- a*
25. The formulation of Claim 24, wherein the concentration of Lys^{B28}Pro^{B29}-human insulin is between about 17.5 mg/mL and about 35 mg/mL.
26. The formulation of Claim 22, wherein the phenolic preservative is a mixture of m-cresol and phenol.
27. The formulation of Claim 26, wherein TRIS is present at a concentration of about 2 mg/mL; glycerol is the isotonicity agent and is present at a concentration of about 16 mg/mL; and wherein m-cresol is present at a concentration of about 1.76 mg/mL and phenol is present at a concentration of about 0.715 mg/mL.
28. A stable, soluble formulation of a monomeric insulin analog, for use in a continuous infusion system, consisting essentially of: an isotonicity agent; a buffer selected from the group consisting of TRIS and arginine; Lys^{B28}Pro^{B29}-human insulin; zinc; and a phenolic preservative.
- B*
29. The ~~monomeric insulin analog~~ formulation of Claim 28, which further comprises protamine.
30. A method for treating diabetes comprising administering an effective dose of the formulation of Claim 27 to a patient in need thereof.
31. The method of Claim 30, wherein the formulation is administered using a continuous infusion system.
32. A method for treating ¹⁴ ~~hypoglycemia~~ ^{hyperglycemia} comprising administering an effective dose of the formulation of Claim 27 to a patient in need thereof.